All Posts Tagged With: "EW"
(MDT) MedTech Industry Stock Outlook – March 2012 – Zacks Analyst Interviews
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(MDT) MedTech Industry Stock Outlook – March 2012 – Industry Outlook
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
(EW) Edwards Lifesciences Earns FDA OK on Trial Enrollment
Recently, Edwards Lifesciences Corporation (EW) received conditional approval from the US Food and Drug Administration for enrollment of a certain group of patients in the PARTNER II trial. The trial is studying...
(EW) Edwards Lifesciences 2011 Fourth Quarter Earnings Scorecard
The announcement of Edwards Lifesciences’ (EW) third quarter fiscal 2011 results as on October 19, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011.
Third...
(EW) Edwards Lifesciences Corporation Earnings Preview
Edwards Lifesciences Corporation (EW) is scheduled to release its third quarter fiscal 2011 results on Wednesday, October 19, 2011 after the market closes.
The company is expected to earn 39 cents per...
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(EW) Edwards Lifesciences Announces Share Buyback
Edwards Lifesciences Corporation (EW) recently announced a new share repurchase program worth $500 million. At the end of the second quarter of fiscal 2011, the company was left with $240 million of authorization....
(EW) Edwards Lifesciences Sapien Under Centers for Medicare & Medicaid Services NCA
Edwards Lifesciences (EW) received a major setback as the Centers for Medicare & Medicaid Services (CMS) decided to initiate a National Coverage Analysis (NCA) of transcatheter aortic valve replacement...
(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook
June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected...
(AEO) Company News for August 25, 2011 – Corporate Summary
25Aug2011 | vitalstocks | 0 comments | Continued
(BPI) Company News for July 26, 2011 – Corporate Summary
• Kimberly-Clark (NYSE:KMB) reported Q2 adjusted EPS of $1.18, surpassing the Zacks Consensus Estimate of $1.15 per share. Revenues for the quarter rose 8% year-over-year to $5.3 billion, exceeding the Zacks Consensus...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook
A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of...
(EW) Edwards Lifesciences’ Sapien Transcatheter Heart Valve on Way to Success
Recently, Edwards Lifesciences (EW) presented positive data for its Cohort A of the PARTNER trial at the American College of Cardiology annual conference in New Orleans. The PARTNER trial is evaluating Edwards’...
(EW) Edwards Lifesciences to Present PARTNER Data
Edwards Lifesciences (EW), will present data from the Cohort A of the PARTNER trial at the American College of Cardiology annual conference in New Orleans in early April.
The PARTNER trial is evaluating...
(BSX) Boston Scientific Earns CE Mark Stent Approval
Boston Scientific Corporation (BSX) recently received the CE Mark approval for its Omega Platinum Chromium Bare-Metal Coronary Stent System,...
(DXCM) DexCom Analyst Reiterates Stock at Neutral
We reaffirm our Neutral recommendation on DexCom Inc (DXCM), a prominent player in the continuous glucose monitoring market. Second-quarter fiscal 2010 loss per share of 20 cents matched the Zacks Consensus...
(BSX) Boston Scientific Hears Good News From Food and Drug Administration
Recently, Boston Scientific (BSX) received a notice from the Food and Drug Administration (FDA), whereby all the issues cited in the Company’s 2006 corporate warning letter have been resolved.
The...
(DXCM) DexCom Quarterly Loss Higher Than Expected
DexCom, Inc. (DXCM) reported a loss of 27 cents per share in the first quarter, 3 cents above the Zacks Consensus Estimate of a loss of 24 cents but well below the year-ago loss of 33 cents.
Revenues...
(ATSI) ATS Medical Receives Canadian Approval
ATS Medical, Inc. (ATSI) recently received the Health Canada-Medical Device Bureau, Therapeutic Products Programme’s approval for commercialization of the ATS Simulus Annuloplasty Product Line for valve...
(DXCM) DexCom Reports Smaller Loss on Increased Revenues
DexCom, Inc. (DXCM) reported a net loss of 25 cents per share in the fourth quarter of 2009, a couple cents narrower than the Zacks Consensus Estimate for a net loss of 27 cents and significantly narrower...
(ATSI) ATS Medical Analysts Downgrade The Stock
We recently downgraded ATS Medical, Inc. (ATSI) to ‘Underperform’ with a target price of $2.30 based on a P/S of 2.0x our fiscal 2010 revenue estimate of $82 million.
ATS Medical recently reported...
(ATSI) ATS Medical Fourth Quarter Reports Weak Results
ATS Medical Inc. (ATSI) recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, loss per share was 3 cents, higher than the Zacks Consensus Estimate of 1 cent and the year-ago figure...
(BAX) Baxter International Reports Earnings In-Line
Baxter International Inc. (BAX) reported financial results for the fourth quarter and full fiscal 2009. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate and...
(ATSI) ATS Medical Raises Expectations
ATS Medical, Inc. (ATSI) reported preliminary results for the fourth quarter and full fiscal 2009. The company expects total revenues in the fourth quarter in the range of $18.4 million to $18.8 million,...
(ATSI) ATS Medical Gets CE Approval
ATS Medical, Inc. (ATSI) recently received CE Mark approval to distribute the ATS 3f Enable Aortic Bioprosthesis in the European Union. The Enable valve is implanted using a sutureless technique. It is the...
(ATSI) ATS Medical Earnings Report Meets Consensus
ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents.